We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

VTGN VistaGen Therapeutics Inc

0.07 (1.44%)
Pre Market
Last Updated: 07:00:11
Delayed by 15 minutes


Draw Mode:

Volume 269
Bid Price 4.93
Ask Price 5.01
News -
Day High


52 Week Range


Day Low
Company Name Stock Ticker Symbol Market Type
VistaGen Therapeutics Inc VTGN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.07 1.44% 4.94 07:00:11
Open Price Low Price High Price Close Price Prev Close
Trades Volume Avg Volume 52 Week Range
19 269 - 1.62 - 24.71
Last Trade Time Type Quantity Stock Price Currency
07:00:04 1 $ 5.00 USD

VistaGen Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
131.6M 27.02M - -227k -59.25M -2.19 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

VistaGen Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No VTGN Message Board. Create One! See More Posts on VTGN Message Board See More Message Board Posts

Historical VTGN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.625.183.474.49919,8831.3236.46%
1 Month2.885.182.45013.67743,3652.0671.53%
3 Months6.096.232.45013.64593,203-1.15-18.88%
6 Months2.7824.711.627.971,222,6092.1677.7%
1 Year3.6024.711.625.263,350,9381.3437.22%
3 Years24.30106.501.6222.203,757,569-19.36-79.67%
5 Years52.80106.501.6222.192,538,867-47.86-90.64%

VistaGen Therapeutics Description

Vistagen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Vistagen's pipeline includes six product candidates, including five clinical-stage investigational agents belonging to a new class of drugs known as pherines. Its portfolio includes PH94B, a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia. PH10, an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression.

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 |